Questions may not always match the order of those online. Please be sure to read the questions when completing the online test.

Size: px
Start display at page:

Download "Questions may not always match the order of those online. Please be sure to read the questions when completing the online test."

Transcription

1 Module 13 Part 1 Questions may not always match the order of those online. Please Case #1 Fred W. Fred W. is in to see you for a referral from his family physician. In the referral letter, the family physician mentions that he has diagnosed Fred with prediabetes. He asks if you can provide him some education to reduce his risk of progression to type 2 diabetes. From his referral letter you see the following information: Patient - Fred W. Age 48 years old Weight 225 lbs, BMI 32 kg/m 2 Blood pressure = 148/94 mmhg LDL cholesterol = 3.8 mmol/l HDL cholesterol = 0.7 mmol/l Current medications: o Perindopril 8 mg daily started 1 week ago o Rosuvastatin 10 mg daily started 1 week ago Fasting blood glucose: o 6.3 mmol/l 2 hour 75-g oral glucose tolerance test: o 8.6 mmol/l Fred has some questions regarding why he is having this problem with sugar control. You start to provide him some information on the pathophysiology of diabetes. 1. You discuss the role of insulin in the body. Which of the following statements regarding insulin is TRUE? a. Insulin is an anabolic hormone b. When food is ingested insulin decreases glycogen levels c. Insulin levels are increased during low glucose levels to suppress glyconeogenesis d. Insulin suppresses lipid formation in the adipocytes 2. You start discussing glucagon. Which of the following statements regarding glucagon is TRUE? a. It promotes the conversion of glycogen to glucose b. It prevents gluconeogenesis c. After 1 hour of fasting, it promotes the formation of glucose from non-carbohydrate substrates d. It suppresses ketogenesis 3. You decide to review the other main hormones involved in glycemic control. Which of the following statements is TRUE? a. Gastric inhibitory peptide (GIP) inhibits the release of insulin b. Catecholamines has a similar effect to insulin c. Glucocorticoids stimulate gluconeogenesis 1

2 d. Growth hormone promotes the effect of insulin 4. Fred asks about what causes type 2 diabetes. Which of the following is linked to the development of type 2 diabetes? a. An increase in the number of β-cells in the pancreas b. High levels of insulin secretion after food ingestion c. Decreasing levels of insulin resistance d. Genetic predisposition for glucose intolerance 5. Fred asks if there could be other causes of diabetes. You review his medication history for drugrelated causes of diabetes. Which of the following agents have been linked to the development of hyperglycemia? a. Cyclosporine b. Phenytoin c. Thiazide diuretics 6. You discuss other options to reduce Fred s risk of developing type 2 diabetes. Which of the following medications does NOT decrease the risk of developing type 2 diabetes in patients with prediabetes? a. Orlistat b. Acarbose c. Rosiglitazone d. Repaglinide 7. You review impact of lifestyle modifications on Fred s risk of developing type 2 diabetes. In the Finish diabetes prevention study, what was the reduction in the risk of developing type 2 diabetes from a low calorie, low fat, low saturated fat, high fibre diet, combined with moderate intensity exercise of at least 150 minutes per week? a. 10% b. 26% c. 58% d. 72% 8. You start to review the diagnosis criteria for prediabetes with Fred. Which of the following readings would be classified in the prediabetes range? a. Fasting blood glucose of 7.2 mmol/l b. Fasting blood glucose of 6.4 mmol/l c. 2 hour plasma glucose in the 75 g OGTT of 7.2 mmol/l d. 2 hour plasma glucose in the 75 g OGTT of 11.4 mmol/l 9. Fred asks at what blood sugar level would he be diagnosed with type 2 diabetes. Which of the following readings is in the range for diagnosis of a patient with type 2 diabetes? a. A1C of 6.7% b. 2 hour plasma glucose in the 75 g OGTT of 9.2 mmol/l c. Fasting plasma glucose of 6.8 mmol/l 2

3 Case #2 Katie S. Katie S. is in to see you for diabetes education. She was referred to you by her family doctor as she was recently diagnosed with type 2 diabetes. She was started on metformin 500 mg BID and she has very little knowledge of how to properly manage her diabetes. She was also told to purchase a blood glucose meter to start testing her blood sugar. The referral letter reveals the following: Patient - Katie S. Age 52 years old Weight 160 lbs, BMI 27 kg/m 2 Blood pressure = 132/81 mmhg LDL cholesterol = 2.7 mmol/l HDL cholesterol = 1.2 mmol/l Current medications: o Metformin 500 mg BID Last A1C result = 8% You feel the best way to start is to provide her education on her glycemic targets. 10. Katie asks if her A1C reading is in the target range. Is Katie s current reading in the recommended range a. Yes, she is currently in the A1C target range b. No, she is not in the current A1C target range 11. Katie asks about how often she should have her A1C blood test. What does the CDA guidelines recommend for A1C testing frequency in patients who are having their therapy adjusted? a. Every month b. Every 3 months c. Every 5 months d. Annually 12. She says that she thought an A1C reading of 8% was equivalent to blood glucose reading of 8 mmol/l. You explain that this is not the case. What is the estimated average blood glucose for Katie with an A1C of 8%? a. 8.6 mmol/l b mmol/l c mmol/l d mmol/l 13. You demonstrate the use of a blood glucose meter for Katie. What is the recommended selfmonitoring of blood glucose (SMBG) testing frequency for Katie? a. Once daily b. Twice daily c. Four times daily d. Tailored based on the patient and their targets 3

4 14. You have worked with Katie to determine the optimal SMBG testing frequency. She asks what her readings should be. Which of the following readings would be a recommended target range for most patients with diabetes? a. 3.8 mmol/l fasting reading b. 7.6 mmol/l fasting reading c. 7.8 mmol/l 2 hour post-prandial reading d mmol/l 2 hour post-prandial reading 15. You move your discussion to the nutritional management of diabetes. You start with carbohydrates. Which of the following statements regarding carbohydrates is TRUE? a. They are the largest energy source in patients with diabetes b. Approximately 60% of ingested carbohydrates are converted to glucose in the blood stream c. The CDA recommends the carbohydrate intake to be 25-30% of the total energy intake d. The source of carbohydrates has little response in the conversion to glucose in the bloodstream 16. You start discussing the glycemic index with Katie. Which of the following foods would be classified as having a high glycemic index? a. Sweet potato b. Popcorn c. Rye bread d. Corn flakes 17. Katie asks about sugar free products. You start with a discussion of sugar alcohols. What is the recommended maximum intake of sugar alcohols per day? a. 1 gram/day b. 5 grams/day c. 10 grams/day d. 15 grams/day 18. Which of the following sweeteners is considered safe in patients like Katie? a. Sucrose b. Fructose c. Saccharin 19. You start discussing the role of fibre in Katie s diet. Which of the following statements regarding dietary fibre is TRUE? a. Patients with diabetes should be encouraged to eat a minimum of 10 g of fibre per day b. Wheat bran is an example of soluble fibre c. Soluble fibre may also help control blood glucose levels by slowing gastric emptying and delaying the absorption of glucose into the bloodstream d. It may increase the absorption of cholesterol from the gastrointestinal tract 20. You move the discussion to protein consumption. Which of the following statements regarding protein intake in diabetes is TRUE? a. 30% of the protein ingested is converted to glucose in the blood stream b. In the standard diet, it has a major impact on blood glucose levels c. There is no limitations on the intake of protein in patients with diabetes 4

5 d. Common sources include eggs, lentils and tofu 21. You discuss the role of dietary fat in diabetes with Katie. Which of the following statements regarding dietary fat in diabetes is TRUE? a. Fat consumption usually causes a significant increase in blood glucose levels b. Fat consumption increases the digestion of food c. Fat intake should be limited to < 35% of the total daily energy intake d. The main reason to limit fat consumption is its role in microvascular complications 22. Katie asks about alcohol intake in patients with diabetes. Which of the following statements is a suitable recommendation for patients with diabetes? a. Patients with diabetes should avoid alcohol b. Moderate alcohol consumption with food commonly causes hyperglycemia in patients with type 2 diabetes c. If Katie drinks alcohol she should she never drink alone d. The recommended weekly maximum for Katie would be 14 standard drinks per week 23. What is the recommended minimum amount of moderate intensity aerobic physical activity per week for Katie? a. 30 minutes b. 60 minutes c. 120 minutes d. 150 minutes 24. You move the discussion to her metformin therapy. Which of the following statements regarding metformin is TRUE? a. As monotherapy it will reduce A1C levels by 1-2% b. The maximum daily dose is 1000 mg per day c. It is not recommended in patients with a creatinine clearance of < 60 ml/min d. Lactic acidosis occurs in approximately 1 per 1,000 patient years Katie returns 6 months later. She is currently taking metformin 1000 mg BID. She is not reaching her A1C target. Her last A1C reading was 8.4%. Her family physician wants a suggestion on different therapies that could be added to her metformin therapy. 25. Which of the following therapies could be an option for Katie to add to her metformin therapy? a. Gliclazide b. Pioglitazone c. Liraglutide 26. You discuss the different options with Katie. Which of the following statements regarding insulin secretagogues is TRUE? a. Out of the sulfonylureas the risk of hypoglycemia is lowest with glimepiride b. The average weight gain with a meglitinides agent is kg c. If we were to initiate gliclazide MR therapy, the starting dose would be 60 mg daily d. Risk of hypoglycemia is less common in elderly patients due to increased elimination of these drugs 5

6 27. You start discussing other therapies for Katie to consider in addition to her metformin. Which of the following statements is TRUE? a. Katie is contraindicated to receiving pioglitazone as she is taking metformin therapy b. If we were to initiate Katie on acarbose the starting dose should be 100 mg TID c. If Katie s renal function was a concern she should avoid DPP-4 inhibitors d. If Katie was to initiate liraglutide therapy she could expect a 3 kg weight loss 28. You finish your review of the different options by discussing the efficacy of combination therapy. Which of the following therapies added to metformin is UNLIKELY to help Katie reach her A1C target? a. Insulin b. Sitagliptin c. Gliclazide d. Repaglinide 29. Katie s uncle recently had some pain in his feet and his doctor said it was associated with his diabetes. You explain that this is a condition called diabetic peripheral neuropathy. How common is detectable diabetic peripheral neuropathy in patients within 10 years of the onset of type 1 or type 2 diabetes? a. 5-8% b % c % d % 30. You discuss diabetic peripheral neuropathy with Katie. Which of the following statements is TRUE? a. As many as 50% of patients with the condition are asymptomatic b. The only affected areas are the feet and legs c. Pain occurs in approximately 50% of patients with diabetic peripheral neuropathy d. Patients with type 2 diabetes should start screening 5 years after diagnoses of diabetes 31. She wants to know if she is at a higher risk of this condition. Which of the following is NOT a risk factor for diabetic peripheral neuropathy? a. Hyperglycemia b. Duration of diabetes c. Short stature d. Hypertension 6

7 Case # 3 Carly Y. Carly Y. is in to see you for her quarterly appointment for her diabetes management. She was diagnosed with type 1 diabetes approximately 9 years ago when she was 10 years old. Over the last few appointments you have noticed a worsening of glycemic control. You decide to address this with Carly. She admits that she has been so busy at university that she has not focussed on the management of her diabetes. She says that she is having trouble remember all of the different aspects of diabetes care as her parents used to do almost everything and the bulk of her education occurred years ago when she was a child. You take a look at her chart and see that her regimen is: Insulin glargine 20 units at bedtime Insulin aspart sliding scale prior to each of her meals Her average daily prandial aspart dose is 16 units/day 32. You decide to review the key concepts of carbohydrate management with Carly. Which of the following statements regarding carbohydrate intake in type 1 diabetes is TRUE? a. Carly should choose products with a higher glycemic index b. Carly should attempt to ingest the same amount of carbohydrates at consistent times during the day c. She should be taught to eat the same carbohydrate sources each day d. Her current regimen offers little flexibility for varying carbohydrate intake 33. You review carbohydrate counting with Carly. Which of the following statements is TRUE? a. Carbohydrate counting allows for Carly to eat varying amounts of carbohydrate without causing glycemic excursions b. Carbohydrate counting is important as each carbohydrate affect blood glucose levels very differently c. Carbohydrate counting is only recommended for type 1 diabetes d. Every patient with diabetes has the same recommended amount of carbohydrate servings per meal 34. If her total intake of carbohydrates is 160 grams per day, what is her carbohydrate:insulin ratio based on the daily carbohydrate method? a. 2 b. 7 c. 10 d You decide to calculate Carly s carbohydrate:insulin ratio using the rule of 500. What is this value? a. 2 b. 14 c. 36 d

8 36. You ask Carly what is her insulin sensitivity factor, she is unsure. Using the rule of 100, what is Carly s insulin sensitivity factor? a. 1 b. 3 c. 5 d Carly has some questions regarding her insulin regimen. Which of the following statements is TRUE regarding her insulin glargine? a. It is more effective than NPH insulin at reducing A1C b. It has a lower rate of nocturnal hypoglycemia but a higher rate of overall hypoglycemia compared to NPH insulin c. There is greater intra-patient variability with insulin glargine compared to NPH insulin d. Insulin glargine primarily targets Carly s fasting blood glucose readings 38. You start discussing insulin aspart with Carly. Which of the following is a property of insulin aspart? a. Onset of action 30 minutes b. Peak 30 minutes c. Duration 3-5 hours 39. When reviewing Carly s logbook you notice she is having a significant number of hypoglycemic episodes. You decide to review the proper management of hypoglycemia. You start by discussing symptoms. Which of the following is a neurogenic symptom of hypoglycemia? a. Confusion b. Sweating c. Headache d. Weakness 40. You decide to review some of the risk factors for hypoglycemia with Carly. Which of the following is NOT a hypoglycemia risk factor? a. Skipping a meal b. Physical activity c. Renal dysfunction d. Weight gain 41. You are concerned that Carly may be experiencing some nocturnal hypoglycemia. Which of the following is a symptom of nocturnal hypoglycemia a. Headache b. Nightmares c. Difficulty getting up in the morning 42. Carly explains that she does not commonly have many of the symptoms of hypoglycemia like tremor, palpitations and tingling. You feel she is experiencing hypoglycemia unawareness. Which of the following is a risk factor for hypoglycemia unawareness? a. Younger patients b. Obese patients with diabetes c. Those recently diagnosed with diabetes 8

9 d. Patients with infrequent bouts of hypoglycemia 43. If Carly has a severe hypoglycemic reaction, which of the following is an appropriate initial strategy? a. If conscious, ingest 15 grams of carbohydrates b. If conscious, ingest 20 grams of carbohydrates c. If unconscious, ingest 15 grams of carbohydrates d. If unconscious, be administered 1.5 mg of glucagon subcutaneously 44. You notice that Carly has not been adherent to her screening for microvascular complications. You decide to review this with Carly. Which of the following is screening frequency is recommend for patients with type 1 diabetes? a. Screening for chronic kidney annually from the time of diagnosis b. Screening for chronic kidney annually with duration of diabetes > 5 years c. Screening for retinopathy annually from the time of diagnosis d. Screening every 6 months in all patients > 15 years of age 45. You are concerned about her risk of diabetic nephropathy. Which of the following is NOT a recommendation to help to reduce her risk of diabetic nephropathy? a. Blood pressure control b. Lipid control c. High fluid intake d. Smoking cessation 46. You finish by reviewing contraception and sexual health with Carly. Which of the following statements are TRUE? a. Patients with type 1 diabetes are at higher risk of acquiring sexually transmitted infections b. Only oral contraceptives and condoms are recommended as methods of birth control in patients with diabetes c. Sexual dysfunction is common in women with type 1 diabetes 47. You review the importance of discussing any pregnancy plans with you before she starts trying to become pregnant. Which of the following is a recommendation for preconception care in patients with type 1 diabetes? a. A1C level should be less than 2% above target range b. She should be have an ophthalmologic exam as soon as she becomes pregnant c. She should be initiated on folic acid mg at least 3 months preconception and 12 weeks post-conception d. Medications should be evaluated for safety during the preconception stage 9

10 Case 4 Anil G. Anil G. is in to see you for an appointment for initiation of basal insulin. Anil was diagnosed with type 2 diabetes over 5 years ago and his current regimen of metformin 1000 mg BID and gliclazide MR 120 mg once daily is no longer allowing him to reach his glycemic targets. He was sent to you to discuss the initiation of basal insulin as well as he has some specific questions regarding diabetes management. You review his chart and see the following: Patient Anil G. Age 67 yo Weight 240 lbs, BMI 34 kg/m 2 Blood pressure 140/92 mmhg LDL cholesterol 3.6 mmol/l HDL cholesterol 0.8 mmol/l Current medications: o Telmisartan 80 mg daily o Atorvastatin 10 mg daily o ASA 81 mg daily o Citalopram 20 mg daily Last A1C reading: o 8.7% 48. You start by discussing the initiation of basal insulin. Which of the following would be the LEAST appropriate basal insulin choice for Anil? a. Insulin glargine b. Insulin glulisine c. Insulin detemir d. Insulin NPH 49. You discuss the starting dose and titration of insulin for Anil. Which of the following is the MOST appropriate insulin titration regimen for Anil? a. 1 unit once daily at bedtime and increase by 2 units each day until target is reached b. 5 units once daily at bedtime and increase by 3 units each day until target is reached c. 10 units once daily at bedtime and increase by 1 unit each week until target is reached d. 10 units once daily at bedtime and increase by 1 unit each day until target is reached 50. Through your conversation with Anil you feel that he is elevated risk of cardiovascular disease. You decide to counsel Anil about cardiovascular risk in patients with diabetes. Which of the following statements regarding cardiovascular disease in patients with diabetes is TRUE? a. Patients with type 2 diabetes have a 10 fold increase in cardiovascular disease risk compared to the general population b. The rate of cardiovascular mortality and morbidity in patients with diabetes exceeds by 50% the rate predicted by standard cardiovascular risk factors c. Anil would be classified as moderate risk of coronary artery disease 10

11 d. Resting ECG testing is only recommended for patients > 40 years of age 51. Anil mentions to you that he has been suffering from erectile dysfunction. Which of the following statements is TRUE? a. Erectile dysfunction occurs in 34-45% of men with diabetes. b. It is more common in men aged years of age c. Erectile dysfunction occurs 5-8 years earlier compared to men without diabetes d. Erectile dysfunction is much more common in men with type 2 diabetes compared to men with type 1 diabetes 52. Which of the following treatments could be considered for Anil s erectile dysfunction? a. Sildenafil b. Trimix of papaverine, alprostadil and phentolamine c. Vacuum constrictive device 53. Anil mentions that he will be travelling to India in the next few months. Which of the following recommendation is MOST appropriate for Anil? a. He is travelling East and should not require any adjustments of his medications b. Transport Canada will not allow insulin transport in carry-on baggage on the plain c. Insulin should be hand inspected as repeated exposure to x-rays may affect the overall potency d. Patients with diabetes should adjust to the time zone they are travelling to a week before travel 54. Anil mentions that he is travelling to India due to the death of his mother. He mentions the death occurred several months ago and he has been feeling down since then. His physician started him on citalopram to manage the way he is feeling. You discuss the impact of depression on diabetes control. Which of the following is associated with patients with diabetes and depressive disorders? a. Poorer self-care behaviour b. Decreased quality of life c. Increased family problems 55. When managing a senior with diabetes, which of the following should you consider? a. Assure that he reaches the target A1C level of 7.0% b. Use a similar approach for all seniors with diabetes c. Simplify the regimen as much as possible d. Initiate aggressive treatment as all seniors are at high risk of complications 56. You mention to Anil that he has to be involved in most of the decisions regarding his diabetes as he is the one that has to make the commitment to implement these changes in his life. What percentage of care decisions are made by the patient outside the clinical practice setting? a. 10% b. 25% c. 50% d. 90% 57. You want to empower Anil to take better care of his diabetes. Which of the following is NOT part of the 5 A s of the empowerment education model? 11

12 a. Acceptance b. Abstain c. Alliance d. Active participation 58. You feel through your assessment Anil has a basic Self-Management Education (SME) level. Which of the following best describes this SME level? a. This is the education level that patients with diabetes require for survival b. This is knowledge, skills and motivation to achieve optimal self-care c. This is the knowledge, skills and motivation for self-care that involves a full integration of care into the individual s life activities and goals d. None of the above 59. Which of the following is NOT a principle of adult education in patients with diabetes such as Anil? a. Lectured learning is the optimal teaching method b. Adult life experiences are rich resources for learning c. Information provided should have immediate application d. Adults want to know What s in it for me? 60. Anil mentions that he will start the insulin injections today. Based on the transtheoretical model, what stage of change is Anil currently in for initiating insulin therapy? a. Precontemplation b. Contemplation c. Preparation d. Action 61. If you are considering offering lectures to educate patients with diabetes. Which of the following should you consider? a. Avoid engaging the audience as this can inhibit learning b. Start with complex topics and end with simple topics c. Vary pace and delivery d. When designing lectures include large amounts of content as most adults will retain using this method. 62. Which of the following is NOT a key principle of motivational interviewing? a. Expressing empathy b. Help the patient develop discrepancy c. Insisting to the patient that your point of view is optimal d. Support self-efficacy 63. You ask Anil if he would prefer group learning. Which of the following is an advantage of group discussions? a. Allows for exploration, reflection and critical analysis of an issue b. Helps the patient develop effective and attentive listening skills c. Group discussion also helps to facilitate group cohesiveness and sharing 12

Complete this CE activity online at ProCE.com/InsulinPart2

Complete this CE activity online at ProCE.com/InsulinPart2 Complete this CE activity online at ProCE.com/InsulinPart2 Case 1: A 67 year old male with T2DM History and Presentation John is a 67 year old retiree who has been visiting your pharmacy/clinic for over

More information

Quick Reference Guide

Quick Reference Guide 2013 Clinical Practice Guidelines Quick Reference Guide (Updated November 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING

More information

Application of the Diabetes Algorithm to a Patient

Application of the Diabetes Algorithm to a Patient Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent

More information

FUNDING: MICIS mandated by Maine Legislature, funded by fees collected from pharmaceutical companies as a cost of doing business in the state.

FUNDING: MICIS mandated by Maine Legislature, funded by fees collected from pharmaceutical companies as a cost of doing business in the state. GOAL: To improve clinical outcomes by delivering upto-date, evidence-based prescribing information, using data and guidelines developed by noncommercial sources FUNDING: MICIS mandated by Maine Legislature,

More information

Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function

Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide

More information

This certificate-level program is non-sponsored.

This certificate-level program is non-sponsored. Program Name: Diabetes Education : A Comprehensive Review Module 5 Intensive Insulin Therapy Planning Committee: Michael Boivin, B. Pharm. Johanne Fortier, BSc.Sc, BPh.LPh, CDE Carlene Oleksyn, B.S.P.

More information

Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone

Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral

More information

Complete Comprehensive Diabetes Educator modules available at CCCEP File #: I-P (Expires: Mar.

Complete Comprehensive Diabetes Educator modules available at   CCCEP File #: I-P (Expires: Mar. CDE Preparation Program Topics (Accredited by CCCEP for 0.5 CEUs/Module section Total = 20 CEUs) Module 1 Pathophysiology of Diabetes 5 segments Module 2 Diabetes and Nutrition 5 segments Module 3 Medications

More information

Drugs used in Diabetes. Dr Andrew Smith

Drugs used in Diabetes. Dr Andrew Smith Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin

More information

Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol

Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients

More information

This case study is supported by an educational grant from Abbott.

This case study is supported by an educational grant from Abbott. Program Name: Planning Committee: When and How to Start or Intensify Insulin Therapy in Your Patients with Type 2 Diabetes Alice Cheng, MD, FRCPC Jean-Francois Yale, MD, CSPQ Lori Berard, RN, CDE Sol Stern,

More information

Diabetes in Pregnancy

Diabetes in Pregnancy Diabetes in Pregnancy Ebony Boyce Carter, MD, MPH Division of Maternal Fetal Medicine Washington University School of Medicine Disclosures I have no financial disclosures to report. Objectives Review the

More information

Management of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control

Management of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight

More information

Diabetes education material. 1. Fasting plasma glucose (FPG) (No caloric intake for at least 8 hours)

Diabetes education material. 1. Fasting plasma glucose (FPG) (No caloric intake for at least 8 hours) How do I assess plasma glucose control? Diabetes education material There are four different ways to assess plasma glucose control: 1. Fasting plasma glucose (FPG) (No caloric intake for at least 8 hours)

More information

DIABETES AND RAMADAN FASTING

DIABETES AND RAMADAN FASTING DIABETES AND RAMADAN FASTING Dr. A. Nigam, M.B.B.S., M.D. (Medicine) Specialist Internal Medicine Al Zahrawi Hospital, Ras Al Khaimah, U.A.E. It is estimated that UAE s population currently stands at approximately

More information

Medications for Diabetes

Medications for Diabetes Medications for Diabetes Sweet, but not too sweet Colette Raymond, Pharm D June 15, 2011 Learning Objectives At the end of this presentation you should be able to: Understand the prevalence and types of

More information

Sample Exam Questions

Sample Exam Questions Disclaimer These are not validated questions. They have been created to enhance your learning and provide practice in reading and answering multiple choice questions. Some questions have been created to

More information

Glucose Control drug treatments

Glucose Control drug treatments Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients

More information

Quick Reference Guide

Quick Reference Guide 2018 Clinical Practice Guidelines Quick Reference Guide 416569-18 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Screening and Diagnosis Assess risk ANNUALLY if: Family history (First-degree

More information

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia

More information

Quick Reference Guide

Quick Reference Guide 2018 Clinical Practice Guidelines Quick Reference Guide 416569-18 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Screening and diagnosis of type 2 diabetes in adults Assess risk factors for

More information

Common Diabetes-related Terms

Common Diabetes-related Terms Common Diabetes-related Terms A1C An A1C test measures a person's average blood glucose level over two to three months. Hemoglobin is the part of a red blood cell that carries oxygen to the cells and sometimes

More information

Endo 2 SLO Practice (online) Page 1 of 7

Endo 2 SLO Practice (online) Page 1 of 7 Endo 2 SLO Practice (online) Page 1 of 7 1. A long- acting insulin, like Lantus is for? A. When the next meal is within 30-60 minutes of the injection B. Over night use or for ½ of the day often combined

More information

Diabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Diabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free

More information

New Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum

New Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is

More information

Wayne Gravois, MD August 6, 2017

Wayne Gravois, MD August 6, 2017 Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion

More information

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010 Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number

More information

What s New on the Horizon: Diabetes Medication Update

What s New on the Horizon: Diabetes Medication Update What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:

More information

Vipul Lakhani, MD Oregon Medical Group Endocrinology

Vipul Lakhani, MD Oregon Medical Group Endocrinology Vipul Lakhani, MD Oregon Medical Group Endocrinology Disclosures None Objectives Be able to diagnose diabetes and assess control Be able to identify appropriate classes of medications for diabetes treatment

More information

Objectives. Kidney Complications With Diabetes. Case 10/21/2015

Objectives. Kidney Complications With Diabetes. Case 10/21/2015 Objectives Kidney Complications With Diabetes Brian Boerner, MD Diabetes, Endocrinology, and Metabolism University of Nebraska Medical Center Review screening for, and management of, albuminuria Review

More information

The Many Faces of T2DM in Long-term Care Facilities

The Many Faces of T2DM in Long-term Care Facilities The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment

More information

Diabetes Overview. How Food is Digested

Diabetes Overview. How Food is Digested Diabetes Overview You are The Teacher, The Coach and the Fan Pathophysiology of Diabetes Complications Know the Numbers Treatment Can Good Control Make a Difference? Can Tight Control Be too Tight? How

More information

A Practical Approach to the Use of Diabetes Medications

A Practical Approach to the Use of Diabetes Medications A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE

More information

Management of Type 2 Diabetes

Management of Type 2 Diabetes Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity

More information

Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND THE OLDER ADULT

Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND THE OLDER ADULT Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND THE OLDER ADULT Objectives u At conclusion of the presentation the participant will: 1. Discuss challenges to glycemic control unique in the older population

More information

DIABETES DEBATE - IS NEW BETTER?

DIABETES DEBATE - IS NEW BETTER? DIABETES DEBATE - IS NEW BETTER? WHAT MEDICATION CLASS AFTER METFORMIN TO CONTROL BLOOD SUGAR Dr. Lydia Hatcher, MD, CCFP, FCFP, CHE, D-CAPM Associate Clinical Professor of Family Medicine, McMaster Chief

More information

Diabetes Mellitus Type 2

Diabetes Mellitus Type 2 Diabetes Mellitus Type 2 What is it? Diabetes is a common health problem in the U.S. and the world. In diabetes, the body does not use the food it digests well. It is hard for the body to use carbohydrates

More information

Hypoglycemia. When recognized early, hypoglycemia can be treated successfully.

Hypoglycemia. When recognized early, hypoglycemia can be treated successfully. Hypoglycemia Introduction Hypoglycemia is a condition that causes blood sugar level to drop dangerously low. It mostly shows up in diabetic patients who take insulin. When recognized early, hypoglycemia

More information

Choosing a Diabetes Strategy Where to Start and Where to Go

Choosing a Diabetes Strategy Where to Start and Where to Go Choosing a Diabetes Strategy Where to Start and Where to Go Erin Keely, MD, FRCPC; and Sharon Brez, RN, BScN, MA(Ed), CDE As presented at the University of Ottawa's 52nd Annual Refresher Course for Family

More information

Starting and Helping People with Type 2 Diabetes on Insulin

Starting and Helping People with Type 2 Diabetes on Insulin Starting and Helping People with Type 2 Diabetes on Insulin Elaine Cooke, BSc(Pharm), RPh, CDE Pharmacist and Certified Diabetes Educator Maple Ridge, BC Objectives After attending this session, participants

More information

The Pharmacist s Approach to Primary Care Management of Type 2 Diabetes

The Pharmacist s Approach to Primary Care Management of Type 2 Diabetes CONTINUING EDUCATION The Pharmacist s Approach to Primary Care Management of Type 2 Diabetes By James R. Taylor, PharmD, CDE U pon successful completion of this continuing education activity, the pharmacist

More information

Case study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease

Case study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease Case study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease Authored by Paul Zimmet and Richard Nesto on behalf of the Global Partnership for Effective Diabetes Management.

More information

INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION

INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott

More information

American Diabetes Association: Standards of Medical Care in Diabetes 2015

American Diabetes Association: Standards of Medical Care in Diabetes 2015 American Diabetes Association: Standards of Medical Care in Diabetes 2015 Synopsis of ADA standards relevant to the 11 th Scope of Work under Task B.2 ASSESSMENT OF GLYCEMIC CONTROL Recommendations: Perform

More information

Adult Diabetes Clinician Guide NOVEMBER 2017

Adult Diabetes Clinician Guide NOVEMBER 2017 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.

More information

What s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA

What s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,

More information

Type 2 Diabetes Mellitus 2011

Type 2 Diabetes Mellitus 2011 2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose

More information

APPENDIX American Diabetes Association. Published online at

APPENDIX American Diabetes Association. Published online at APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no

More information

Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate

Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million

More information

BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH

BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH Insulin Initiation BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH Disclosures In the past 12 months, I have received speakers honoraria from AstraZeneca, Boehringer Ingelheim,

More information

Julie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education

Julie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education MENTOR QI Diabetes Performance Improvement Initiative, Getting Patients to Goal in Glycemic Control: Current Data Julie White, MS Administrative Director Boston University School of Medicine Continuing

More information

Metformin Hydrochloride

Metformin Hydrochloride Metformin Hydrochloride 500 mg, 850 mg, 500 mg LA and 750 mg LA Tablet Description Informet is a preparation of metformin hydrochloride that belongs to a biguanide class of oral antidiabetic drugs. Metformin

More information

Diabetes mellitus. Treatment

Diabetes mellitus. Treatment Diabetes mellitus Treatment Recommended glycemic targets for the clinical management of diabetes(ada) Fasting glycemia: 80-110 mg/dl Postprandial : 100-145 mg/dl HbA1c: < 6,5 % Total cholesterol: < 200

More information

Tips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital

Tips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure

More information

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team

More information

YOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013

YOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early

More information

Dept of Diabetes Main Desk

Dept of Diabetes Main Desk Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is

More information

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients

More information

Chief of Endocrinology East Orange General Hospital

Chief of Endocrinology East Orange General Hospital Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage

More information

Modified version focused on CCNC Quality Measures and Feedback Processes

Modified version focused on CCNC Quality Measures and Feedback Processes Executive Summary: Standards of Medical Care in Diabetes 2010 Modified version focused on CCNC Quality Measures and Feedback Processes See http://care.diabetesjournals.org/content/33/supplement_1/s11.full

More information

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice. Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to

More information

Comprehensive Diabetes Treatment

Comprehensive Diabetes Treatment Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes

More information

Case study: Lean adult with no complications, newly diagnosed with type 2 diabetes

Case study: Lean adult with no complications, newly diagnosed with type 2 diabetes Case study: Lean adult with no complications, newly diagnosed with type 2 diabetes Authored by Clifford Bailey and James LaSalle on behalf of the Global Partnership for Effective Diabetes Management. The

More information

Managing diabetes in Ramadan

Managing diabetes in Ramadan 2nd EASD Postgraduate Course on Clinical Diabetes and its Complications Shiraz, Iran, 2-4 March 2017 Managing diabetes in Ramadan Fereidoun Azizi, M.D. Farhad Hosseinpanah, M.D. Research institute for

More information

Standards of Care in Diabetes What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE

Standards of Care in Diabetes What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE Standards of Care in Diabetes 2016-- What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE Terminology No longer using the term diabetic. Diabetes does not define people. People

More information

CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia

CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia Javier Carrasco, MD, PhD Juan Ramón Jiménez Hospital University of Huelva, Spain Case Study: Medical and Social History A 60 years old female

More information

Diabetes in the UK: Update on Diabetes Treatment and Care. Why is diabetes increasing? Obesity Increased waist circumference.

Diabetes in the UK: Update on Diabetes Treatment and Care. Why is diabetes increasing? Obesity Increased waist circumference. Update on Diabetes Treatment and Care Tahseen A Chowdhury Consultant Diabetologist Royal London and Mile End Hospitals Diabetes prevalence (thousands) Diabetes in the UK: 1995-21 3 25 2 15 1 5 Type 1 Type

More information

Diabetes Management in New Brunswick Nursing Homes

Diabetes Management in New Brunswick Nursing Homes Diabetes Management in New Brunswick Nursing Homes Prepared by Dr. Angela McGibbon March, 2016 As the population ages and with the rising incidence of diabetes, there are increasing numbers of people with

More information

Why do we care? 20.8 million people. 70% of people with diabetes will die of cardiovascular disease. What is Diabetes?

Why do we care? 20.8 million people. 70% of people with diabetes will die of cardiovascular disease. What is Diabetes? What is Diabetes? Diabetes 101 Ginny Burns RN MEd CDE Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action

More information

Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary

Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions

More information

RCHC Clinical Guidelines Type 2 Diabetes; Adults

RCHC Clinical Guidelines Type 2 Diabetes; Adults RCHC Clinical Guidelines Type 2 Diabetes; Adults Screening for diabetes in asymptomatic adults 1 Population: Aged > 45 years; Aged < 45 years who are overweight (BMI> 25kg/m 2 ) and have an additional

More information

I. General Considerations

I. General Considerations 1 2 3 I. General Considerations A. Type I ( Juvenile Onset or IDDM) IDDM results from autoimmune destruction of beta cells inability to secrete insulin --> ketone formation --> DKA 4 Diabetic Ketoacidosis

More information

Pre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes

Pre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes Pre-diabetes Pharmacological Approaches to Delay Progression to Diabetes Overview Definition of Pre-diabetes Risk Factors for Pre-diabetes Clinical practice guidelines for diabetes Management, including

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

Module 5. Understanding Insulin Therapy

Module 5. Understanding Insulin Therapy Module 5. Understanding Insulin Therapy EDUCATIONAL OBJECTIVES Upon completion of this activity, participants will be better able to: 1. Define the basic physiologic concept of basal-bolus insulin; 2.

More information

Metabolic Syndrome: What s so big about BIG?

Metabolic Syndrome: What s so big about BIG? Tuesday, 10:00 11:30, A2 Objectives: Notes: Metabolic Syndrome: What s so big about BIG? Patrice Conrad pbconrad1@att.net 1. Identify advances in clinical assessment and management of selected healthcare

More information

DIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013

DIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013 DIABETES Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes November 2013 mbruskewitz@outlook.com Objectives Part 1 Overview of Endocrine Physiology Pathophysiology of Diabetes Diabetes

More information

DIABETES WITH PREGNANCY

DIABETES WITH PREGNANCY DIABETES WITH PREGNANCY Prof. Aasem Saif MD,MRCP(UK),FRCP (Edinburgh) Maternal and Fetal Risks Diabetes in pregnancy is associated with risks to the woman and to the developing fetus. Maternal and Fetal

More information

Have participants measure their blood pressure daily at a standard time for two weeks. Obtain BP values from participant (fax, call, , mail).

Have participants measure their blood pressure daily at a standard time for two weeks. Obtain BP values from participant (fax, call,  , mail). Blood Pressure Management and Control Protocol BP Management: A) BP goal: Achieve blood pressure values less than 130/80mmHg. B) Process: Have participants measure their blood pressure daily at a standard

More information

Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010

Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes

More information

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin) Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your

More information

Individualizing Care for Patients with Type 2 Diabetes

Individualizing Care for Patients with Type 2 Diabetes Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches

More information

Insulin Initiation and Intensification. Disclosure. Objectives

Insulin Initiation and Intensification. Disclosure. Objectives Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School

More information

In-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University

In-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University In-Hospital Management of Diabetes Dr Benjamin Schiff Assistant Professor McGill University No conflict of interest to declare CLINICAL SCENARIO 62 y/o male with hx of DM 2, COPD, and HT is admitted with

More information

Medical Nutrition Therapy for Diabetes Mellitus. Raziyeh Shenavar MSc. of Nutrition

Medical Nutrition Therapy for Diabetes Mellitus. Raziyeh Shenavar MSc. of Nutrition Medical Nutrition Therapy for Diabetes Mellitus Raziyeh Shenavar MSc. of Nutrition Diabetes Mellitus A group of diseases characterized by high blood glucose concentrations resulting from defects in insulin

More information

GLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks

GLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the

More information

Diabetes Mellitus in Older Adults. Presenter Disclosure Information

Diabetes Mellitus in Older Adults. Presenter Disclosure Information Diabetes Mellitus in Older Adults Medha Munshi, M.D. Joslin Diabetes Center Beth Israel Deaconess Medical Center Harvard Medical School Presenter Disclosure Information Medha Munshi Research grant from

More information

Management of Diabetes New Concepts New Devices New Medications. Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth

Management of Diabetes New Concepts New Devices New Medications. Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth Management of Diabetes New Concepts New Devices New Medications Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth Objectives: At the end of this lecture, the learner will

More information

Disclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare

Disclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011

More information

CASE A2 Managing Between-meal Hypoglycemia

CASE A2 Managing Between-meal Hypoglycemia Managing Between-meal Hypoglycemia 1 I would like to discuss this case of a patient who, overall, was doing well on her therapy until she made an important lifestyle change to lose weight. This is a common

More information

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations

More information

Treat-to-Target Tools

Treat-to-Target Tools TEAMcare Care Manager Primary Care Provider Treat to Target Discussion Tool for Treatment Enhancement Activation and Motivation (TEAM) Depression, Diabetes and Coronary Heart Disease (CHD) Intervention

More information

MANAGEMENT OF DIABETES IN PREGNANCY

MANAGEMENT OF DIABETES IN PREGNANCY MANAGEMENT OF DIABETES IN PREGNANCY Ministry of Health Malaysia Malaysian Endocrine & Metabolic Society Perinatal Society of Malaysia Family Medicine Specialists Association of Malaysia Academy of Medicine

More information

6.1. Feeding specifications for people with diabetes mellitus type 1

6.1. Feeding specifications for people with diabetes mellitus type 1 6 Feeding 61 Feeding specifications for people with diabetes mellitus type 1 It is important that the food intake of people with DM1 is balanced, varied and that it meets the caloric needs, and takes into

More information

Hypertension Clinical case scenarios for primary care

Hypertension Clinical case scenarios for primary care Hypertension Clinical case scenarios for primary care Implementing NICE guidance August 2011 NICE clinical guideline 127 What this presentation covers Five clinical case scenarios, including: presentation

More information

Management of DM in Older Adults: It s not all about sugar! Who needs treatment for DM? Peggy Odegard, Pharm.D., BCPS, CDE

Management of DM in Older Adults: It s not all about sugar! Who needs treatment for DM? Peggy Odegard, Pharm.D., BCPS, CDE Management of DM in Older Adults: It s not all about sugar! Peggy Odegard, Pharm.D., BCPS, CDE Who needs treatment for DM? 87 year old, frail male with moderately severe dementia living in NH with persistent

More information

INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE

INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT

More information

Normal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption),

Normal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption), Normal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption), in which blood glucose predominantly originates from

More information

第十五章. Diabetes Mellitus

第十五章. Diabetes Mellitus Diabetes-1/9 第十五章 Diabetes Mellitus 陳曉蓮醫師 2/9 - Diabetes 羅東博愛醫院 Management of Diabetes mellitus A. DEFINITION OF DIABETES MELLITUS Diabetes Mellitus is characterized by chronic hyperglycemia with disturbances

More information

Rhonda Eustice, PharmD, CDE. Will Power lasts about two weeks and is soluble in alcohol. Mark Twain

Rhonda Eustice, PharmD, CDE. Will Power lasts about two weeks and is soluble in alcohol. Mark Twain Rhonda Eustice, PharmD, CDE Will Power lasts about two weeks and is soluble in alcohol. Mark Twain Diabetes Management: The Three Legged Stool Diet Medication Exercise Objectives Know the treatment goals

More information